Development of chronic kidney and cardiovascular diseases in Germany

Figure: Cost development and resource scarcity due to chronic cardiovascular and kidney diseases.

By 2028/29, more than 30% of the total German healthcare budget will have to be spent on these two diseases alone, which will already exceed the system's capabilities. Almost simultaneously, a reduction in the number of available specialists is expected from 2030 at the latest.

The consequence will be triage. From this point onwards, the patients affected will increasingly no longer be able to always receive the vital treatments they need. This is already being experienced by those with statutory health insurance and is increasing on a daily basis.

From 2028/29, this will apply to all patients who require short-term medical care due to the acute consequences of cardiovascular and kidney diseases. Even among private patients, privileged care will only be available to a few.

This inevitable development can still be avoided if the molecular definition and detection of chronic diseases before organ damage occurs is implemented, enabling efficient treatment with the optimal targeted medication.

Worldwide, only proteome analysis offers the possibility of early detection and targeted, efficient therapy. The increase in chronic diseases and their costs can be stopped and even reduced if the proteome analysis of the protexam test is introduced immediately.

TIME to ACT!

Waiting for the catastrophe to occur in 2028/29 will prevent timely countermeasures. Early detection measures require a lead time of 2-3 years before the reduction in advanced chronic diseases has a noticeable effect.